{"paper_id":"e8d54509-47ba-4a6d-bf2a-5bc8605df734","body_text":"Abstract\nObjective\nTo investigate long non-coding RNA (lncRNA) MIR210HG expression in high-grade serous ovarian cancer (HGSOC) and its correlation with clinicopathological features, clinical outcomes, and prognosis.\nMethods\nTissue samples were collected from 84 patients with HGSOC undergoing surgical treatment at the Affiliated Hospital of Qingdao University from 2019 to 2021. Fifty-seven patients undergoing total hysterectomy and bilateral adnexectomy resection for uterine fibroids and adenomyosis during the same period were also included. MIR210HG expression was detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Univariate and multivariate logistic regression analyses were used to assess correlation with advanced FIGO stage and clinical outcomes. The Kaplan-Meier plotter was used to predict the correlation between MIR210HG expression and prognosis, considering pathological classification, clinical stage, and TP53 status.\nResults\nMIR210HG expression was significantly upregulated in HGSOC compared to normal ovarian and fallopian tube tissues. MIR210HG expression was moderately and weakly correlated with CA125 (r = 0.515, P < 0.001) and HE4 levels (r = 0.325, P = 0.001), respectively. Advanced clinical stage was associated with higher MIR210HG expression. Patients with lymph node metastasis and ascites also exhibited higher MIR210HG expression (P < 0.05). MIR210HG was associated with FIGO stage, while CA125 ≤ 35 U/ml and FIGO stage II were independent protective factors for composite poor clinical outcomes. Patients with low MIR210HG expression had a significantly longer 5-year progression-free survival (PFS) compared to those with high expression. What’s more, MIR210HG expression was significantly correlated with both 5-year PFS and overall survival (OS) in TP53-mutant patients, as opposed to only OS in TP53 wild-type patients.\nConclusion\nMIR210HG expression is significantly upregulated in HGSOC and is associated with clinical stage, lymph node metastasis, and ascites. MIR210HG expression exhibited survival associations based on TP53 status, suggesting biomarker potential for HGSOC.\nAcknowledgements\nThe authors thank Editage (www.editage.cn) for English language editing.\nFunding\nThis work was supported by the Natural Science Fund Project of Shandong Province [ZR2019MH127] and the Key Research and Development Plan of Shandong Province [2019GSF108106].\nAuthor information\nAuthors and Affiliations\nCorresponding authors\nEthics declarations\nEthics approval and consent to participate\nThe study was approved by the Ethical Committee of the Affiliated Hospital of Qingdao University (approval number: QYFY WZLL 27332). All methods were performed in accordance with the relevant guidelines and regulations of the Ethical Committee of the Affiliated Hospital of Qingdao University. All participants provided informed consent.\nConsent for publication\nAll authors have consented to the publication of this article.\nCompeting interests\nThe authors declare no competing interests.\nAdditional information\nPublisher’s note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nSupplementary Information\nBelow is the link to the electronic supplementary material.\nRights and permissions\nOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.\nAbout this article\nCite this article\nSun, N., Chen, A. Expression level of lncRNA MIR210HG in high-grade serous ovarian cancer tissues and its correlation with clinicopathological features and prognosis. Discov Onc (2026). https://doi.org/10.1007/s12672-026-05882-5\nReceived:\nAccepted:\nPublished:\nDOI: https://doi.org/10.1007/s12672-026-05882-5","source_license":"CC0","license_restricted":false}